- Q1 2024 Curis Inc Earnings Call TranscriptMay 07, 2024$16.2 (+0.19%)Earnings
- Q4 2023 Curis Inc Earnings Call TranscriptFeb 08, 2024$10.65 (+13.42%)Earnings
- Q3 2023 Curis Inc Earnings Call TranscriptNov 02, 2023$4.51 (-4.25%)Earnings
- Q2 2023 Curis Inc Earnings Call TranscriptAug 03, 2023$15.42 (-2.98%)Earnings
- Q1 2023 Curis Inc Earnings Call TranscriptMay 04, 2023$16.76 (+3.48%)Earnings
- Q4 2022 Curis Inc Earnings Call TranscriptMar 13, 2023$11.51 (-8.40%)Earnings
- Curis Inc to Discuss Updated Emavusertib Clinical Data Call TranscriptDec 12, 2022
- Q3 2022 Curis Inc Earnings Call TranscriptNov 09, 2022$14.44 (-7.44%)Earnings
- Q2 2022 Curis Inc Earnings Call TranscriptAug 04, 2022$19.78 (+0.91%)Earnings
- Q1 2022 Curis Inc Earnings Call TranscriptMay 05, 2022$18.2 (-9.00%)Earnings
- Curis Inc at Needham Healthcare Conference (Virtual) - On-Demand TranscriptApr 12, 2022
- Q4 2021 Curis Inc Earnings Call TranscriptFeb 24, 2022$63.4 (+8.19%)Earnings
- Curis Inc to Discuss Positive Updated Clinical Data on Phase 1/2 Monotherapy Study of CA-4948 and Initial Clinical Data from Phase 1 Study of CI-8993 Call TranscriptJan 06, 2022
- Q3 2021 Curis Inc Earnings Call TranscriptNov 09, 2021$114.4 (-4.83%)Earnings
- Curis Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- Curis Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 30, 2021
- Curis Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Curis Inc Earnings Call TranscriptAug 03, 2021$139.8 (-9.46%)Earnings
- Curis Inc to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA Virtual Congress TranscriptJun 11, 2021
- Curis Inc Annual Shareholders Meeting TranscriptMay 27, 2021
- Q1 2021 Curis Inc Earnings Call TranscriptMay 12, 2021$325.4 (+65.51%)Earnings
- Q4 2020 Curis Inc Earnings Call TranscriptMar 16, 2021$211 (-4.26%)Earnings
- Curis Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-recorded TranscriptMar 09, 2021
- Curis Inc Virtual KOL Event - Reviewing CA-4948 Clinical Data in NHL & AML/MDS TranscriptDec 08, 2020
- Q3 2020 Curis Inc Earnings Call TranscriptNov 10, 2020$22.8 (+5.56%)Earnings
- Q2 2020 Curis Inc Earnings Call TranscriptAug 04, 2020$26.4 (+10.92%)Earnings
- Curis Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Q1 2020 Curis Inc Earnings Call TranscriptMay 12, 2020$17.51 (+1.70%)Earnings
- Curis Inc at Needham Healthcare Conference TranscriptApr 14, 2020
- Q4 2019 Curis Inc Earnings Call TranscriptMar 19, 2020$14.73 (+1.94%)Earnings
- Curis Inc Corporate Call TranscriptDec 06, 2019
- Q3 2019 Curis Inc Earnings Call TranscriptNov 05, 2019$39 (-19.75%)Earnings
- Q2 2019 Curis Inc Earnings Call TranscriptAug 06, 2019$46.4 (+0.87%)Earnings
- Q1 2019 Curis Inc Earnings Call TranscriptMay 14, 2019$38.2 (+3.24%)Earnings
- Q4 2018 Curis Inc Earnings Call TranscriptMar 26, 2019$40.2 (+6.35%)Earnings
- Curis Inc at Cowen Health Care Conference TranscriptMar 13, 2019
Curis Inc to Discuss Updated Emavusertib Clinical Data Call Transcript
Good morning, and welcome to Curis' Call for the 2022 ASH Conference Call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to James Dentzer, President and CEO of Curis. Please go ahead.
Thank you, and good morning, everyone. Thank you for joining us. On the call today, we have Bob Martell, our Head of R&D, who will be sharing the latest clinical data from our TakeAim Leukemia study. We're also pleased to have Eric Winer, our Clinical Director of Adult Leukemia at Dana-Farber joining us to add his perspective.
With that, let's get started. Bob?
Great. Thank you, Jim. So I am very excited to share the updated clinical data for emavusertib in AML and high-risk MDS, which further reinforce monotherapy activity of emavusertib. From preclinical work and past clinical studies, we've identified targeted
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)